Aquestive Therapeutics Inc (NASDAQ:AQST) price target raised to $30.00 by Wedbush

Analyst Ratings For Aquestive Therapeutics Inc (NASDAQ:AQST)

Today, Wedbush raised its price target on Aquestive Therapeutics Inc (NASDAQ:AQST) to $30.00 per share.

There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Aquestive Therapeutics Inc (NASDAQ:AQST) is Buy with a consensus target price of $27.6667 per share, a potential 216.91% upside.

Some recent analyst ratings include

  • 8/20/2018-Aquestive Therapeutics Inc (NASDAQ:AQST) has coverage initiated with a Outperform rating and $29.00 price target
  • 8/20/2018-Aquestive Therapeutics Inc (NASDAQ:AQST) has coverage initiated with a Outperform rating


    About Aquestive Therapeutics Inc (NASDAQ:AQST)
    Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates that are in development comprise AQST-203, a buccally, an administered soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; AQST-120, an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy; and AQST-117, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's development products also include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; AQST-305, a buccal film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors; APL-130277, a sublingual film formulation of apomorphine to treat episodic off-periods in Parkinson's disease; AQST-119, an oral soluble film formulation of tadalafil to treat erectile dysfunction; and AQST-306, a film formulation of edaravone. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.

    Recent Trading Activity for Aquestive Therapeutics Inc (NASDAQ:AQST)
    Shares of Aquestive Therapeutics Inc closed the previous trading session at 8,56 up +1,01 13,31 % with shares trading hands.

    An ad to help with our costs